

Emily L Heil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5575594/publications.pdf>

Version: 2024-02-01

102
papers

1,899
citations

218381

26
h-index

301761

39
g-index

104
all docs

104
docs citations

104
times ranked

2613
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to McFarland et al. <i>Clinical Infectious Diseases</i> , 2022, 74, 942-943.	2.9	0
2	The Goldilocks Time for Remdesivir " Is Any Indication Just Right?. <i>New England Journal of Medicine</i> , 2022, 386, 385-387.	13.9	14
3	In a Pinch: Cefiderocol for CRAB Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0006522.	1.4	6
4	Does calculation method matter for targeting vancomycin area under the curve?. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2245-2250.	1.3	1
5	Selection by design: Using job analysis to guide the selection of postgraduate pharmacy residents. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1570-1579.	0.5	1
6	Real-world Antimicrobial Stewardship Experience in a Large Academic Medical Center: Using Statistical and Machine Learning Approaches to Identify Intervention "Hotspots" in an Antibiotic Audit and Feedback Program. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	6
7	A Cross-sectional Analysis of Linezolid in Combination with Methadone or Buprenorphine as a Cause of Serotonin Toxicity. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	6
8	Change in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1115-1117.	1.0	28
9	Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. <i>Clinical Infectious Diseases</i> , 2021, 72, 541-552.	2.9	103
10	The Economics of Penicillin Allergy Testing: Still Scratching the Value Surface. <i>Clinical Infectious Diseases</i> , 2021, 72, 939-941.	2.9	5
11	Policy statement from the Society for Healthcare Epidemiology of America (SHEA): Only medical contraindications should be accepted as a reason for not receiving all routine immunizations as recommended by the Centers for Disease Control and Prevention. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1-5.	1.0	14
12	Cefiderocol: the Trojan horse has arrived but will Troy fall?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 153-155.	4.6	19
13	Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	19
14	Impact of a C. difficile infection (CDI) reduction bundle and its components on CDI diagnosis and prevention. <i>American Journal of Infection Control</i> , 2021, 49, 319-326.	1.1	2
15	An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 265-271.	0.9	4
16	Effectiveness and Safety of Biodegradable Calcium Sulfate Antibiotic Beads as Adjuvant Therapy in Vascular Graft Infections. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa650.	0.4	4
17	Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection. <i>Infectious Diseases and Therapy</i> , 2021, 10, 605-612.	1.8	6
18	Evaluation of Intra-Operative Topical Vancomycin and the Incidence of Acute Kidney Injury. <i>Surgical Infections</i> , 2021, 22, 810-817.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Toward More Rational Time-to-Antibiotic Metrics for Suspected Sepsis*. Critical Care Medicine, 2021, 49, 858-860.	0.4	3
20	A Multicenter Evaluation of Probiotic Use for the Primary Prevention of <i>Clostridioides difficile</i> Infection. Clinical Infectious Diseases, 2021, 73, 1330-1337.	2.9	19
21	Streptococcus pyogenes Infective Endocarditis Association With Injection Drug Use: Case Series and Review of the Literature. Open Forum Infectious Diseases, 2021, 8, ofab240.	0.4	2
22	Antibiogram Development in the Setting of a High Frequency of Multi-Drug Resistant Organisms at University Teaching Hospital, Lusaka, Zambia. Antibiotics, 2021, 10, 782.	1.5	6
23	New Perspectives on Antimicrobial Agents: Cefiderocol. Antimicrobial Agents and Chemotherapy, 2021, 65, e0217120.	1.4	65
24	The Impact of Corticosteroids on Secondary Infection and Mortality in Critically Ill COVID-19 Patients. Journal of Intensive Care Medicine, 2021, 36, 1201-1208.	1.3	31
25	The potential impact of discrepancies between automated susceptibility platforms and other testing methodologies for cefazolin in the treatment of Enterobacterales bloodstream infections. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115483.	0.8	1
26	The role of tazobactam-based combinations for the management of infections due to extended-spectrum beta-lactamase-producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2021, 41, 864-880.	1.2	1
27	Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. Open Forum Infectious Diseases, 2021, 8, ofab434.	0.4	31
28	1220. Is MIC all that matters? MIC Distributions of Ceftazidime and Cefepime in Ceftriaxone-Resistant <i>E. coli</i> and <i>Klebsiella</i> spp. Open Forum Infectious Diseases, 2021, 8, S700-S700.	0.4	0
29	Surveying the selection landscape: A systematic review of processes for selecting postgraduate year 1 pharmacy residents and key implications. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 245-256.	0.5	3
30	The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. Current Infectious Disease Reports, 2020, 22, 1.	1.3	34
31	Management of Gram-Negative Bloodstream Infections in the Era of Rapid Diagnostic Testing: Impact With and Without Antibiotic Stewardship. Open Forum Infectious Diseases, 2020, 7, ofaa427.	0.4	22
32	Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen. SAGE Open Medicine, 2020, 8, 205031212096057.	0.7	1
33	Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review. Journal of Infectious Diseases, 2020, 222, S132-S141.	1.9	22
34	Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance. Journal of Infectious Diseases, 2020, 222, S119-S131.	1.9	55
35	Remdesivir: a pendulum in a pandemic. BMJ, The, 2020, 371, m4560.	3.0	4
36	Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care. Antibiotics, 2020, 9, 700.	1.5	25

#	ARTICLE	IF	CITATIONS
37	COVID-19: Pitfalls in Offering Research Participation as Therapy in Clinical Settings. <i>Journal of General Internal Medicine</i> , 2020, 35, 3359-3360.	1.3	0
38	Concurrent COVID-19 and <i>Pneumocystis jirovecii</i> pneumonia in a severely immunocompromised 25-year-old patient. <i>International Journal of Infectious Diseases</i> , 2020, 99, 119-121.	1.5	32
39	A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	16
40	A Propensity Score Matched Study of the Positive Impact of Infectious Diseases Consultation on Antimicrobial Appropriateness in Hospitalized Patients with Antimicrobial Stewardship Oversight. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	8
41	The Clinical Impact of a Negative Molecular β -Lactamase Gene Test for <i>Enterobacteriaceae</i> : Let's Not Let Perfect Be the Enemy of Really Good. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	3
42	Rifabutin Use in <i>Staphylococcus</i> Biofilm Infections: A Case Series. <i>Antibiotics</i> , 2020, 9, 326.	1.5	9
43	Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock. <i>Pharmacotherapy</i> , 2020, 40, 211-220.	1.2	9
44	Recommended Revisions to the National SEP's Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. <i>Pharmacotherapy</i> , 2020, 40, 368-371.	1.2	1
45	Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe <i>Clostridioides difficile</i> Infection. <i>Pharmacotherapy</i> , 2020, 40, 398-407.	1.2	8
46	Antimicrobial usage at a large teaching hospital in Lusaka, Zambia. <i>PLoS ONE</i> , 2020, 15, e0228555.	1.1	19
47	The Effect of Venous-Arterial Extracorporeal Oxygenation and Nasogastric Tube Administration on the Pharmacokinetic Profile of Abacavir, Lamivudine and Dolutegravir: A Case Report. <i>Antiviral Therapy</i> , 2020, 25, 115-119.	0.6	3
48	SPARC-ing Change? The Maryland Statewide Prevention and Reduction of <i>Clostridioides difficile</i> (SPARC) Collaborative. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, s80-s80.	1.0	1
49	274. Comparison of Cefazolin Susceptibilities of Enterobacterales with an Automated Susceptibility Testing Platform versus In Vitro Antimicrobial Testing. <i>Open Forum Infectious Diseases</i> , 2020, 7, S138-S138.	0.4	0
50	Evaluation of Surgical Site Infections After Change in Surgical Prophylaxis in VAD Patients. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, s230-s231.	1.0	0
51	Reply to Letters to the Editor. <i>Pharmacotherapy</i> , 2020, 40, 985-986.	1.2	0
52	Effectiveness of 8 Weeks of Ledipasvir/Sofosbuvir for Hepatitis C in HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2019, 24, 11-17.	0.6	3
53	Self-perceived knowledge and confidence regarding infectious diseases of advanced pharmacy practice experience students. <i>Currents in Pharmacy Teaching and Learning</i> , 2019, 11, 1095-1102.	0.4	2
54	Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2053-2057.	0.9	3

#	ARTICLE	IF	CITATIONS
55	A practical guide for pharmacists to successfully implement penicillin allergy skin testing. American Journal of Health-System Pharmacy, 2019, 76, 136-147.	0.5	31
56	Clinical outcomes of valganciclovir prophylaxis in high-risk (D+/R ⁺) renal transplant recipients experiencing delayed graft function. Transplant Infectious Disease, 2019, 21, e13125.	0.7	5
57	Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections. Infectious Diseases and Therapy, 2019, 8, 171-184.	1.8	74
58	Pharmacists' perceptions of implementing a pharmacist-managed area under the concentration time curve-guided vancomycin dosing program at a large academic medical center. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 482-487.	0.5	3
59	2362. Back to the Future: The Impact of Multi-Step Algorithm C. difficile Testing at a Large Tertiary Medical Center. Open Forum Infectious Diseases, 2019, 6, S813-S814.	0.4	1
60	141. Use of Rapid Diagnostic Testing in Gram-negative Bloodstream Infections with and without Antimicrobial Stewardship. Open Forum Infectious Diseases, 2019, 6, S98-S99.	0.4	0
61	Penicillin skin testing in methicillin-sensitive staphylococcus aureus bacteremia: A cost-effectiveness analysis. PLoS ONE, 2019, 14, e0210271.	1.1	12
62	An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two Cities. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	34
63	The Verigene dilemma: gram-negative polymicrobial bloodstream infections and clinical decision making. Diagnostic Microbiology and Infectious Disease, 2018, 91, 144-146.	0.8	26
64	Accuracy of Provider-Selected Indications for Antibiotic Orders. Infection Control and Hospital Epidemiology, 2018, 39, 111-113.	1.0	12
65	Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention. Current Infectious Disease Reports, 2018, 20, 7.	1.3	29
66	1216. Cost-Effectiveness of Penicillin Skin Allergy Testing in Methicillin-Sensitive Staphylococcus aureus (MSSA) Bacteremia. Open Forum Infectious Diseases, 2018, 5, S369-S369.	0.4	0
67	451. High-Frequency of Multi-Drug-Resistant Organisms (MDRO) at University Teaching Hospital (UTH), Lusaka, Zambia. Open Forum Infectious Diseases, 2018, 5, S169-S170.	0.4	1
68	1050. Oral Antibiotics for the Treatment of Gram-Negative Bloodstream Infections: Prescribing Practices and Outcomes at a Large Academic Medical Center. Open Forum Infectious Diseases, 2018, 5, S313-S314.	0.4	0
69	2138. Impact of De-escalation of Antibiotic Surgical Prophylaxis in Lung Transplant Recipients. Open Forum Infectious Diseases, 2018, 5, S629-S630.	0.4	1
70	488. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridium difficile Infection in Critically Ill Patients. Open Forum Infectious Diseases, 2018, 5, S181-S181.	0.4	2
71	The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria. Expert Opinion on Pharmacotherapy, 2018, 19, 2019-2031.	0.9	10
72	Making the change to area under the curve-based vancomycin dosing. American Journal of Health-System Pharmacy, 2018, 75, 1986-1995.	0.5	68

#	ARTICLE	IF	CITATIONS
73	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: A Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy280.	0.4	83
74	Health care worker perceptions toward computerized clinical decision support tools for <i>Clostridium difficile</i> infection reduction: A qualitative study at 2 hospitals. <i>American Journal of Infection Control</i> , 2018, 46, 1160-1166.	1.1	12
75	Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	42
76	The Cost of Self-Reported Penicillin Allergy: A Systematic Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1649-1654.e4.	2.0	93
77	Treatment strategies for persistent methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 614-625.	0.7	51
78	Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	92
79	Allergy profile should be updated after uneventful administration of a penicillin or penicillin-related antibiotic to a patient with penicillin allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 184-186.	2.0	10
80	Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 328-333.	0.8	5
81	Appropriate Antibiotic Therapy. <i>Emergency Medicine Clinics of North America</i> , 2017, 35, 25-42.	0.5	33
82	Indications for Antibiotic Orders: How Accurate Are They?. <i>Open Forum Infectious Diseases</i> , 2017, 4, S325-S325.	0.4	0
83	Impact of a Multi-disciplinary <i>C. difficile</i> Action Team. <i>Open Forum Infectious Diseases</i> , 2017, 4, S396-S397.	0.4	0
84	Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients. <i>Open Forum Infectious Diseases</i> , 2017, 4, S27-S27.	0.4	1
85	Implementation of an Infectious Disease Fellow-Managed Penicillin Allergy Skin Testing Service. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw155.	0.4	58
86	Outcomes with Ceftazidime/Avibactam in Patients with Carbapenem-Resistant <i>Pseudomonas</i> Infections: A Multi-Center Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
87	Agricultural Applications for Antimicrobials. A Danger to Human Health: An Official Position Statement of the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2016, 36, 422-432.	1.2	15
88	Advancing interprofessional patient safety education for medical, nursing, and pharmacy learners during clinical rotations. <i>Journal of Interprofessional Care</i> , 2016, 30, 819-822.	0.8	18
89	Outcomes With Ceftazidime/Avibactam in Patients With Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: A Multi-center Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	2
90	Impact of Changes in Urine Culture Ordering Practice on Antimicrobial Utilization in Intensive Care Units at an Academic Medical Center. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 448-454.	1.0	29

#	ARTICLE	IF	CITATIONS
91	The Essential Role of Pharmacists in Antimicrobial Stewardship. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 753-754.	1.0	45
92	Commentary: Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs. <i>Journal of Clinical Microbiology</i> , 2016, 54, 840-844.	1.8	40
93	Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 953-967.	0.9	56
94	Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1899-1901.	1.4	35
95	Are Fluoroquinolones Appropriate for the Treatment of Extended-Spectrum β -Lactamase-Producing Gram-Negative Bacilli?. <i>Journal of Pharmacy Technology</i> , 2016, 32, 16-21.	0.5	18
96	Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. <i>Surgical Infections</i> , 2015, 16, 829-832.	0.7	8
97	Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Using Extended-Infusion Antimicrobial Regimens. <i>Pharmacotherapy</i> , 2015, 35, 54-58.	1.2	7
98	Rapid Testing Using the Verigene Gram-Negative Blood Culture Nucleic Acid Test in Combination with Antimicrobial Stewardship Intervention against Gram-Negative Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1588-1595.	1.4	77
99	What does the pharmacological future of treating chronic hepatitis C look like?. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 605-622.	1.3	5
100	Resistance Patterns of <i>Escherichia coli</i> in Women with Uncomplicated Urinary Tract Infection Do Not Correlate with Emergency Department Antibigram. <i>Journal of Emergency Medicine</i> , 2015, 49, 998-1003.	0.3	13
101	Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of <i>Candida</i> infections. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1910-1914.	0.5	57
102	Assessment of antimicrobial pharmacokinetics curricula across schools and colleges of pharmacy in the United States. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	0